Non-monoaminergic targets for the development of antidepressants: Focus on neuropeptides

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 2-10

  Catena Dell'Osso, Mario ^a   Fagiolini, Andrea ^b   Marazziti, Donatella ^c   Baroni, Stefano ^c   Bellantuono, Cesario ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Antidepressants; Corticotropin releasing factor receptor antagonists; Galanin; Major depressive disorder; Nemifitide; Neurokinin receptor antagonists; Neuropeptides; Vasopressin receptor antagonists

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2, 5 DIMETHYLPYRAZOLO [1, 5 A] PYRIMIDINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL) ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; 8 (2, 4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL) ETHYLAMINO] 2, 7 DIMETHYLPYRAZOLO [1, 5 A] [1, 3, 5] TRIAZINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; ANTALARMIN; ANTIDEPRESSANT AGENT; APREPITANT; ATC0065; ATC0175; BUTYL [2, 5 DIMETHYL 7 (2, 4, 6 TRIMETHYLPHENYL) 7H PYRROLO [2, 3 D] PYRIMIDIN 4 YL] ETHYLAMINE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CASOPITANT; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CP 311; CP 316; EMICERFONT; GALANIN; GSK586529; GW803430; JNJ19567470; L 759274; MELANIN CONCENTRATING HORMONE; NBI 34101; NELIVAPTAN; NETAMIFTIDE; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; ONO2333MS; OXYTOCIN; PEXACERFONT; PROLYLLEUCYLGLYCINAMIDE; SNAP 94847; SUBSTANCE P; TAI 041; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN; VASOPRESSIN V1B RECEPTOR; VERUCERFONT;

ABSENCE OF SIDE EFFECTS; ARTICLE; DRUG TARGETING; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84875021187     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955713804484758     Document Type: Article

References (105)

1. Murray, C.J.L.; Lopez, A.D. Evidence-based health policy-lessons from the global burden of disease study. Science, 1996, 274(5288), 740-743.
2. Lopez, A.D.; Murray, C.C. The global burden of disease, 1990-2020. Nature Med., 1998, 4(11), 1241-1243.
3. rded.; Cambridge University Press: New York, 2008.
4. Marazziti, D.; Catena Dell'Osso, M.; Consoli, G.; Baroni, S. Second messenger modulation: a novel target of future antidepressants? Curr. Med. Chem., 2009, 16, 4679-4690.
5. World Health Organization. Data and Statistics. www.who.int/research/en. Accessed September 16, 2010.
6. Kinney, G.G.; Taber, M.T.; Gribkoff, V.K. The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Mol. Neurobiol., 2000, 21(3), 137-152.
7. Kintscher, U. Reuptake inhibitors of dopamine, noradrenaline, and serotonin. Handb. Exp. Pharmacol., 2012, 209, 339-347.
8. Marazziti, D.; Catena-Dell'Osso, M. The role of oxytocin in neuropsychiatric disorders. Curr. Med. Chem., 2008, 15(7), 698-704.
9. Zarate, C. Jr; Machado-Vieira, R; Henter, I.; Ibrahim, L.; Diazgranados, N.; Salvadore, G. Glutamatergic modulators: the future of treating mood disorders? Harv. Rev. Psychiatry, 2010, 18(5), 293-303.
10. Paschos, K.A.; Veletza, S.; Chatzaki, E. Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression. CNS Drugs, 2009, 23(9), 755-772.
11. Catena-Dell'Osso, M.; Bellantuono, C.; Consoli, G.; Baroni, S.; Rotella, F.; Marazziti, D. Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr. Med. Chem., 2011, 18, 245-255.
12. Rotzinger, S.; Lovejoy, D.A.; Tan, L.A. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides, 2010, 31(4), 736-756.
13. Faravelli, C.; Catena, M.; Scarpato, A.; Ricca, V. Epidemiology of life events: life events and psychiatric disorders in the Sesto Fiorentino study. Psychother. & Psychosom., 2007, 76(6), 361-368.
14. Faravelli, C.; Amedei, S.G.; Rotella, F.; Faravelli, L.; Palla, A.; Consoli, G.; Ricca, V.; Batini, S.; Lo Sauro, C.; Spiti, A.; Catena-Dell'Osso, M. Childhood traumata, Dexamethasone Suppression Test and psychiatric symptoms: a trans-diagnostic approach. Psychol. Med., 2010, 40, 2037-2048.
15. Pariante, C.M.; Lightman, S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci., 2008, 31(9), 464-468.
16. Griebel, G.; Simiand, J.; Serradeil-Le Gal, C.; Wagnon, J.; Pascal, M.; Scatton, B.; Maffrand, J.P.; Soubrie, P. Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. U.S.A., 2002, 99(9), 6370-6375.
17. Griebel, G.; Simiand, J.; Steinberg, R.; Jung, M.; Gully, D.; Roger, P.; Geslin, M.; Scatton, B.; Maffrand, J.P.; Soubrié, P. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylp henyl)ethyl]5-methyl-N-(2-ropynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stressrelated disorders. J. Pharmacol. Exp. Ther., 2002, 301(1), 333-345.
18. Ducottet, C.; Griebel, G.; Belzung, C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27(4), 625-631.
19. Holmes, A.; Heilig, M.; Rupniak, N.M.; Steckler, T.; Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci., 2003, 24(11), 580-588.
20. Chang, M.M.; Leeman, S.E. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J. Biol. Chem., 1970, 245, 4784-4790.
21. Adell, A.; Castro, E.; Celada, P.; Bortolozzi, A.; Pazos, A.; Artigas, F. Strategies for producing faster acting antidepressants. Drug Discov Today, 2005, 10(8), 578-585.
22. Kramer, M.S.; Cutler, N.; Feighner, J.; Shrivastava, R.; Carman, J.; Sramek, J.J.; Reines, S.A.; Liu, G.; Snavely, D.; Wyatt-Knowles, E.; Hale, J.J.; Mills, S.G.; MacCoss, M.; Swain, C.J.; Harrison, T.; Hill, R.G.; Hefti, F.; Scolnick, E.M.; Cascieri, M.A.; Chicchi, G.G.; Sadowski, S.; Williams, A.R., Hewson, L.; Smith, D.; Carlson, E.J.; Hargreaves, R.J.; Rupniak, N.M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 1998, 281(5383), 1640-1645.
23. Stockmeier, C.A.; Shi, X.; Konick, L.; Overholser, J.C.; Jurjus, G.; Meltzer, H.Y.; Friedman, L.; Blier, P.; Rajkowska, G. Neurokinin-1 receptors are decreased in major depressive disorder. Neuroreport, 2002, 13(9), 1223-1227.
24. Geracioti, T.D.; Carpenter, L.L.; Owens, M.J.; Baker, D.G.; Ekhator, N.N.; Horn, P.S.; Strawn, J.R.; Sanacora, G.; Kinkead, B.; Price, L.H.; Nemeroff, C.B. Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. Am. J. Psychiatry, 2006, 163(4), 637-643.
25. Kramer, M.S.; Winokur, A.; Kelsey, J.; Preskorn, S.H.; Rothschild, A.J.; Snavely, D.; Ghosh, K.; Ball, W.A.; Reines, S.A.; Munjack, D.; Apter, J.T.; Cunningham, L.; Kling, M.; Bari, M.; Getson, A.; Lee, Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology, 2004, 29(2), 385-392.
26. Keller, M.; Montgomery, S.; Ball, W.; Morrison, M.; Snavely, D.; Liu, G.; Hargreaves, R.; Hietala, J.; Lines, C.; Beebe, K.; Reines, S. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry, 2006, 59(3), 216-223.
27. Ratti, E.; Bellew, K.; Bettica, P.; Bryson, H.; Zamuner, S.; Archer, G.; Squassante, L.; Bye, A.; Trist, D.; Krishnan, K.R.; Fernandes, S. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J. Clin. Psychopharmacol., 2011, 31(6), 727-733.
28. Vale, W.; Spiess, J.; Rivier, C.; Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science, 1981, 213(4514), 1394-1397.
29. Hauger, R.L.; Risbrough, V.; Brauns, O.; Dautzenberg, F.M. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol. Disord. Drug Targets, 2006, 5(4), 453-479.
30. Bale, T.L.; Vale, W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 525-557.
31. Hillhouse, E.W.; Grammatopoulos, D.K. The molecular mechanisms underlying the regulation of the biological activity of corticotropinreleasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev., 2006, 27(3), 260-286.
32. Valdez, G.R. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date. CNS Drugs, 2006, 20(11), 887-896.
33. Bale, T.L.; Vale, W.W. Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses. J. Neurosci., 2003, 23, 5295-5301.
34. Nielsen, D.M.; Carey, G.J.; Gold, L.H. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur. J. Pharmacol., 2004, 499(1-2), 135-146.
35. Alonso, R.; Griebel, G.; Pavone, G.; Stemmelin, J.; Le Fur, G.; Soubrié, P. Blockade of CRF(1) or V(1b) receptors reverses stressinduced suppression of neurogenesis in a mouse model of depression. Mol. Psychiatry, 2004, 9(3), 278-286.
36. Chaki, S.; Nakazato, A.; Kennis, L.; Nakamura, M.; Mackie, C.; Sugiura, M.; Vinken, P.; Ashton, D.; Langlois, X.; Steckler, T. Anxiolytic-and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur. J. Pharmacol., 2004, 485(1-3), 145-158.
37. Jutkiewicz, E.M.; Wood, S.K.; Houshyar, H.; Hsin, L.W.; Rice, K.C.; Woods, J.H. The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology, 2005, 180(2), 215-223.
38. Mansbach, R.S.; Brooks, E.N.; Chen, Y.L. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur. J. Pharmacol., 1997, 323(1), 21-26.
39. Takamori, K.; Kawashima, N.; Chaki, S.; Nakazato, A.; Kameo, K. Involvement of the hypothalamus-pituitary-adrenal axis in antidepressant activity of corticotropin-releasing factor subtype 1 receptor antagonists in the rat learned helplessness test. Pharmacol. Biochem. Behav., 2001, 69(3-4), 445-449.
40. Zobel, A.W.; Nickel, T.; Künzel, H.E.; Ackl, N.; Sonntag, A.; Ising, M.; Holsboer, F. Effects of the high-affinity corticotropinreleasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr Res., 2000, 34(3), 171-181.
41. Künzel, H.E.; Zobel, A.W.; Nickel, T.; Ackl, N.; Uhr, M.; Sonntag, A.; Ising, M.; Holsboer, F. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J. Psychiatr. Res., 2003, 37(6), 525-533.
42. Binneman, B.; Feltner, D.; Kolluri, S.; Shi, Y.; Qiu, R.; Stiger, T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry, 2008, 165(5), 617-620.
43. Lundberg, J.M. Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol. Rev., 1996, 48, 113-178.
44. Heilig, M.; McLeod, S.; Brot, M.; Heinrichs, S.C.; Menzaghi, F.; Koob, G.F.; Britton, K.T. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology, 1993, 8, 357-363.
45. Bannon, A.W.; Seda, J.; Carmouche, M.; Francis, J.M.; Norman, M.H.; Karbon, B.; McCaleb, M.L. Behavioral characterization of neuropeptide Y knockout mice. Brain Res., 2000, 868, 79-87.
46. Wahlestedt, C.; Pich, E.M.; Koob, G.F.; Yee, F.; Heilig, M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science, 1993, 259, 528-531.
47. Nakajima, M.; Inui, A.; Asakawa, A.; Momose, K.; Ueno, N.; Teranishi, A.; Baba, S.; Kasuga, M. Neuropeptide Y produces anxiety via Y2-type receptors. Peptides, 1998, 19, 359-363.
48. Tschenett, A.; Singewald, N.; Carli, M.; Balducci, C.; Salchner, P.; Vezzani, A.; Herzog, H.; Sperk, G. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur. J. Neurosci., 2003, 18, 143-148.
49. Bacchi, F.; Mathé, A.A.; Jiménez, P.; Stasi, L.; Arban, R.; Gerrard, P.; Caberlotto, L. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides, 2006, 27, 3202-3207.
50. Morgan, C.A.; Rasmusson, A.M.; Wang, S.; Hoyt, G.; Hauger, R.L.; Hazlett, G. Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol. Psychiatry, 2002, 52, 136-142.
51. Hashimoto, H.; Onishi, H.; Koide, S.; Kai, T.; Yamagami, S. Plasma neuropeptide Y in patients with major depressive disorder. Neurosci. Lett., 1996, 216, 57-60.
52. Czermak, C.; Hauger, R.; Drevets, W.C.; Luckenbaugh, D.A.; Geraci, M.; Charney, D.S.; Neumeister, A. Plasma NPY concentrations during tryptophan and sham depletion in medication-free patients with remitted depression. J. Affect. Disord., 2008, 110(3), 277-281.
53. McCann, S.M.; Brobeck, J.R. Evidence for a role of the supraopticohypophyseal system in regulation of adrenocorticotrophin secretion. Proc. Soc. Exp. Biol. Med., 1954, 87, 318-324.
54. Baertschi, A.J.; Vallet, P.; Baumann, J.B.; Girard, J. Neural lobe of pituitary modulates corticotropin release in the rat. Endocrinology, 1980, 106, 878-882.
55. Aguilera, G.; Rabadan-Diehl, C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul. Pept., 2000, 96, 23-29.
56. Serradeil-Le Gal, C.; Wagnon, J.; Simiand, J.; Griebel, G.; Lacour, C.; Guillon, G.; Barberis, C.; Brossard, G.; Soubrié, P.; Nisato, D.; Pascal, M.; Pruss, R.; Scatton, B.; Maffrand, J.P.; Le Fur, G. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N, N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J. Pharmacol. Exp. Ther., 2002, 300(3), 1122-1130.
57. Griebel, G.; Simiand, J.; Stemmelin, J.; Gal, C.S.; Steinberg, R. The vasopressin V1b receptor as a therapeutic target in stressrelated disorders. Curr. Drug Targets CNS Neurol. Disord., 2003, 2(3), 191-200.
58. Breuer, M.E.; van Gaalen, M.M.; Wernet, W.; Claessens, S.E.; Oosting, R.S.; Behl, B.; Korte, S.M.; Schoemaker, H.; Gross, G.; Olivier, B.; Groenink, L. SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model. Naunyn Schmiedebergs Arch. Pharmacol., 2009, 379(1), 101-106.
59. Hodgson, R.A.; Higgins, G.A.; Guthrie, D.H.; Lu, S.X.; Pond, A.J.; Mullins, D.E.; Guzzi, M.F.; Parker, E.M.; Varty, G.B. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154, 526, in rodent models of anxiety and depression. Pharmacol. Biochem. Behav., 2007, 86(3), 431-440.
60. Iijima, M.; Chaki, S. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(3), 622-627.
61. Gimpl, G.; Fahrenholz, F. The oxytocin receptor system: structure, function, and regulation. Physiol. Rev., 2001, 81, 629-683.
62. Pariante, C.M.; Miller, A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry, 2001, 49, 391-404.
63. Bell, C.J.; Nicholson, H.; Mulder, R.T.; Luty, S. E.; Joyce, P.R. Plasma oxytocin levels in depression and their correlation with the temperament dimension of reward dependence. J. Psychopharmacol., 2006, 20(5), 656-660.
64. Klenerova, V.; Krejci, I.; Sida, P.; Hlinak, Z.; Hynie, S. Modulary effects of oxytocin and carbetocin on stress-induced changes in rat behavior in the open-field. J. Physiol. Pharmacol., 2009, 60(2), 57-62.
65. Chaviaras, S.; Mak, P.; Ralph, D.; Krishnan, L.; Broadbear, J.H. Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. Psychopharmacology, 2010, 210(1), 35-43.
66. Levy, M.I.; DeNigris, Y.; Davis, K.L. Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial. Biol. Psychiatry, 1982, 17(2), 259-263.
67. van der Velde, C.D. Rapid clinical effectiveness of MIF-I in the treatment of major depressive illness. Peptides, 1983, 4(3), 297-300.
68. Ehrensing, R.H.; Kastin, A.J.; Wurzlow, G.F.; Michell, G.F.; Mebane, A.H. Improvement in major depression after low subcutaneous doses of MIF-1. J. Affect. Disord., 1994, 31(4), 227-233.
69. Feighner, J.P.; Sverdlov, L.; Nicolau, G.; Abajian, H.B.; Hlavka, J.; Freed, J.S.; Tonelli, G. Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: comparison of follow-up re-treatment with initial treatment. Int. J. Neuropsychopharmacol., 2003, 6(3), 207-213.
70. Feighner, J.P.; Sverdlov, L.; Hlavka, J.; Nicolau, G.; Cartwright, K.; Freed, J.S. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients. Int. Clin. Psychopharmacol., 2008, 23(1), 29-35.
71. Nicolau, G.; Feighner, J.P.; Stout, R.; Hlavka, J.; Gutierrez, M.; Ciric, S.; Freed, J. Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers. Biopharm. Drug Dispos., 2005, 26(9), 379-385.
72. Montgomery, S.A.; Feighner, J.P.; Sverdlov, L.; Shrivastava, R.K.; Cunningham, L.A.; Kiev, A.; Hlavka, J.; Tonelli, G. Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder. Int. J. Neuropsychopharmacol., 2006, 9(5), 517-28.
73. Evans, H.F.; Shine, J. Human galanin: molecular cloning reveals a unique structure. Endocrinology, 1991, 129, 1682-1684.
74. Schmidt, W.E.; Kratzin, H.; Eckart, K.; Drevs, D.; Mundkowski, G.; Clemens, A.; Katsoulis, S.; Schäfer, H.; Gallwitz, B.; Creutzfeldt, W. Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptide. Proc. Natl. Acad. Sci. U.S. A, 1991, 88(24), 11435-11439.
75. Mitsukawa, K.; Lu, X.; Bartfai, T. Galanin, galanin receptors and drug targets. Cell Mol. Life Sci., 2008, 65(12), 1796-805.
76. Michener, S.R.; Aimone, L.D.; Yaksh, T.L.; Go, V.L. Distribution of galanin-like immunoreactivity in the pig, rat and human central nervous system. Peptides, 1990, 11, 1217-1223.
77. Kuteeva, E.; Hokfelt, T.; Wardi, T.; Ogren, S.O. Galanin, galanin receptor subtypes and depression-like behaviour. Cell Mol. Life Sci., 2008, 65, 1854-1863.
78. Ogren, S.O.; Kuteeva, E.; Hökfelt, T.; Kehr, J. Galanin receptor antagonists: a potential novel pharmacological treatment for mood disorders. CNS Drugs, 2006, 20(8), 633-654.
79. Kehr, J.; Yoshitake, T.; Wang, F.H.; Razani, H.; Gimenez-Llort, L.; Jansson, A.; Yamaguchi, M.; Ogren, S.O. Galanin is a potent in vivo modulator of mesencephalic serotonergic neurotransmission. Neuropsychopharmacology, 2002, 27, 341-356.
80. Khoshbouei, H.; Cecchi, M.; Dove, S.; Javors, M.; Morilak, D.A. Behavioral reactivity to stress: amplification of stress-induced noradrenergic activation elicits a galanin-mediated anxiolytic effect in central amygdala. Pharmacol. Biochem. Behav., 2002, 71, 407-417.
81. Sharkey, L.M.; Madamba, S.G.; Siggins, G.R.; Bartfai, T. Galanin alters GABAergic neurotransmission in the dorsal raphe nucleus. Neurochem. Res., 2008, 33, 285-291.
82. Tyszkiewicz, J.P.; Fong, T.M.; Dong, Y. GABAB receptors are required for galanin modulation of membrane properties of neurons in the arcuate nucleus of rats. Brain Res., 2008, 1191, 63-68.
83. Ottlecz, A.; Snyder, G.D.; McCann, S.M. Regulatory role of galanin in control of hypothalamic-anterior pituitary function. Proc. Natl. Acad. Sci. U.S. A, 1988, 85, 9861-9865.
84. Hooi, S.C.; Maiter, D.M.; Martin, J.B.; Koenig, J.I. Galaninergic mechanisms are involved in the regulation of corticotropin and thyrotropin secretion in the rat. Endocrinology, 1990, 127, 2281-2289.
85. Malendowicz, L.K.; Nussdorfer, G.G.; Nowak, K.W.; Mazzocchi, G. The possible involvement of galanin in the modulation of the function of rat pituitary-adrenocortical axis under basal and stressful conditions. Endocr. Res., 1994, 20, 307-317.
86. Khoshbouei, H.; Cecchi, M.; Morilak, D.A. Modulatory effects of galanin in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuropsychopharmacology, 2002, 27, 25-34.
87. Arvat, E.; Gianotti, L.; Ramunni, J.; Grottoli, S.; Brossa, P.C.; Bertagna, A.; Camanni, F.; Ghigo, E. Effect of galanin on basal and stimulated secretion of prolactin, gonadotropins, thyrotropin, adrenocorticotropin and cortisol in humans. Eur. J. Endocrinol., 1995, 133(3), 300-304.
88. Leibowitz, S.F. Differential functions of hypothalamic galanin cell grows in the regulation of eating and body weight. Ann. N. Y. Acad. Sci., 1998, 863, 206-220.
89. Mazzocchi, G.; Malendowicz, L.K.; Rebuffat, P.; Nussdorfer, G.G. Effects of galanin on the secretory activity of the rat adrenal cortex: in vivo and in vitro studies. Res. Exp. Med., 1992, 192, 373-381.
90. Bartfai, T.; Lu, X.; Badie-Mahdavi, H.; Barr, A.M.; Mazarati, A.; Hua, X.Y., Yaksh, T.; Haberhauer, G.; Ceide, S.C.; Trembleau, L.; Somogyi, L.; Kröck, L.; Rebek, J. Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc. Natl. Acad. Sci. U.S. A, 2004, 101(28), 10470-10475.
91. Lu, X.; Sharkey, L.; Bartfai, T. The brain galanin receptors: targets for novel antidepressant drugs. CNS Neurol. Disord. Drug Targets, 2007, 6(3), 183-192.
92. Kuteeva, E.; Wardi, T.; Hökfelt, T.; Ogren, S.O. Galanin enhances and a galanin antagonist attenuates depression-like behaviour in the rat. Eur. Neuropsychopharmacol., 2007, 17(1), 64-69.
93. Kuteeva, E.; Hökfelt, T.; Wardi, T.; Ogren, S.O. Galanin, galanin receptor subtypes and depression-like behaviour. EXS., 2010, 102, 163-181.
94. Murck, H.; Held, K.; Ziegenbein, M.; Kunzel, H.; Holsboer, F.; Steiger, A. Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. Psychoneuroendocrinology, 2004, 29, 1205-1211.
95. Kawauchi, H.; Kawazoe, I.; Tsubokawa, M.; Kishida, M.; Baker, B.I. Characterization of melanin-concentrating hormone in chum salmon pituitaries. Nature, 1983, 305, 321-323.
96. Hawes, B.E.; Kil, E.; Green, B.; O'Neill, K.; Fried, S.; Graziano, M.P. The melanin-concentrating hormone receptor couples to multiple G proteins to activate diverse intracellular signaling pathways. Endocrinology, 2000, 141, 4524-4532.
97. Hill, J.; Duckworth, M.; Murdock, P.; Rennie, G.; Sabido-David, C.; Ames, R.S.; Szekeres, P.; Wilson, S.; Bergsma, D.J.; Gloger, I.S.; Levy, D.S.; Chambers, J.K.; Muir, A.I. Molecular cloning and functional characterization of MCH2, a novel human MCH receptor. J. Biol. Chem., 2001, 276, 20125-20129.
98. Shimada, M.; Tritos, N.A.; Lowell, B.B.; Flier, J.S.; Maratos-Flier, E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature, 1998, 396, 670-674.
99. Marsh, D.J.; Weingarth, D.T.; Novi, D.E.; Chen, H.Y.; Trumbauer, M.E.; Chen, A.S.; Guan, X.M.; Jiang, M.M.; Feng, Y.; Camacho, R.E.; Shen, Z.; Frazier, E.G.; Yu, H.; Metzger, J.M.; Kuca, S.J.; Shearman, L.P.; Gopal-Truter, S.; MacNeil, D.J.; Strack, A.M.; MacIntyre, D.E.; Van der Ploeg, L.H.; Qian, S. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc. Natl. Acad. Sci. U.S. A, 2002, 99, 3240-3245.
100. Borowsky, B.; Durkin, M.M.; Ogozalek, K.; Marzabadi, M.R.; DeLeon, J.; Lagu, B.; Heurich, R.; Lichtblau, H.; Shaposhnik, Z.; Daniewska, I.; Blackburn, T.P.; Branchek, T.A.; Gerald, C.; Vaysse, P.J.; Forray, C. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat. Med., 2002, 8, 825-830.
101. Chaki, S.; Funakoshi, T.; Hirota-Okuno, S.; Nishiguchi, M.; Shimazaki, T.; Iijima, M.; Grottick, A.J.; Kanuma, K.; Omodera, K.; Sekiguchi, Y.; Okuyama, S.; Tran, T.A.; Semple, G.; Thomsen, W. Anxiolytic-and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J. Pharmacol. Exp. Ther., 2005, 313, 831-839.
102. McBriar, M.D. Recent advances in the discovery of melanin concentrating hormone receptor antagonists. Curr. Opin. Drug Discov. Devel., 2006, 9, 496-508.
103. David, D.J.; Klemenhagen, K.C.; Holick, K.A.; Saxe, M.D.; Mendez, I.; Santarelli, L.; Craig, D.A.; Zhong, H.; Swanson, C.J.; Hegde, L.G.; Ping, X.I.; Dong, D.; Marzabadi, M.R.; Gerald, C.P.; Hen, R. Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3, 4-difluorophenoxy) phenyl]methyl}(4-piperidyl)-4-methylphen yl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. J. Pharmacol. Exp. Ther., 2007, 321, 237-248.
104. Gehlert, D.R.; Rasmussen, K.; Shaw, J.; Li, X.; Ardayfio, P.; Craft, L.; Coskun, T.; Zhang, H.Y.; Chen, Y.; Witkin, J.M. Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. J. Pharmacol. Exp. Ther., 2009, 329, 429-438.
105. Smith, D.G.; Hegde, L.G.; Wolinsky, T.D.; Miller, S.; Papp, M.; Ping, X.; Edwards, T.; Gerald, C.P.; Craig, D.A. The effects of stressful stimuli and hypothalamic-pituitary-adrenal axis activation are reversed by the melanin-concentrating hormone 1 receptor antagonist SNAP 94847 in rodents. Behav. Brain Res., 2009, 197, 284-291.